Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend that T-cell –depleting agents should be used only for kidney transplant (KT) recipients at high immunologic risk. However, the effects of thymoglobulin induction therapy in low–immunologic risk KT recipients on tacrolimus, mycophenolic acid, and steroid have not been elucidated yet.

Source: Transplantation Proceedings - June 1, 2018 Category: Transplant Surgery Authors: H. Lee, S. Lee, J.S. Jeon, S.H. Kwon, H. Noh, D.C. Han, S. Yun, D. Song Tags: Milestones in Transplantation Source Type: research